Ursolic Acid-Standardized Apple Pomace Supplementation for Muscle Strength and Physical Performance in Older Adults With Mild Sarcopenia: A Randomized, Double-Blind, Placebo-Controlled Trial
Key claim: A randomized, double-blind, placebo-controlled trial is testing whether 200–400 mg/day ursolic acid–standardized apple pomace for 12 weeks improves handgrip strength and physical performance in older adults with mild sarcopenia.
Abstract
Sarcopenia is an age-related condition characterized by loss of muscle strength and physical performance, leading to increased risk of falls and disability. This randomized, double-blind, placebo-controlled clinical trial aims to evaluate the effects of ursolic acid-standardized apple pomace supplementation on muscle strength and physical performance in older adults with mild sarcopenia. Participants will be randomly assigned to receive either 200 mg/day, 400 mg/day of the supplement, or placebo for 12 weeks. The primary outcome is change in handgrip strength, with additional assessments of physical performance, body composition, fatigue, and quality of life. The study will also evaluate the safety and tolerability of the intervention.
Why this matters
Ursolic acid has long been proposed as a muscle-supportive triterpenoid on mechanistic grounds (IGF-1/Akt signaling, atrophy gene suppression) but human sarcopenia RCTs are scarce. A standardized apple-pomace preparation entering a placebo-controlled trial with functional endpoints would move ursolic acid from mechanism-plausible toward direct human-outcome evidence — provided the readout eventually publishes.